Hennion & Walsh Asset Management Inc. Takes Position in Indivior PLC (NASDAQ:INDV)

Hennion & Walsh Asset Management Inc. bought a new position in shares of Indivior PLC (NASDAQ:INDV - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 95,935 shares of the company's stock, valued at approximately $1,192,000. Hennion & Walsh Asset Management Inc. owned 0.07% of Indivior at the end of the most recent quarter.

Several other hedge funds have also added to or reduced their stakes in the company. Iron Triangle Partners LP bought a new stake in Indivior in the 3rd quarter valued at about $8,243,000. Krensavage Asset Management LLC acquired a new stake in shares of Indivior in the third quarter valued at approximately $6,843,000. Millennium Management LLC boosted its stake in shares of Indivior by 48.1% in the second quarter. Millennium Management LLC now owns 493,313 shares of the company's stock valued at $7,952,000 after buying an additional 160,282 shares during the period. Stonepine Capital Management LLC acquired a new stake in Indivior during the third quarter worth approximately $2,632,000. Finally, Clark Estates Inc. NY bought a new position in Indivior during the 3rd quarter worth $2,477,000. 60.33% of the stock is owned by institutional investors and hedge funds.

Indivior Price Performance

INDV traded down $0.01 during trading on Friday, hitting $11.65. 1,060,388 shares of the stock traded hands, compared to its average volume of 974,047. The business has a 50 day moving average price of $11.46 and a 200 day moving average price of $11.04. Indivior PLC has a twelve month low of $7.33 and a twelve month high of $23.22. The company has a market cap of $1.61 billion, a price-to-earnings ratio of -291.18 and a beta of 0.74.

Indivior (NASDAQ:INDV - Get Free Report) last posted its quarterly earnings results on Thursday, October 24th. The company reported $0.54 EPS for the quarter, topping analysts' consensus estimates of $0.39 by $0.15. Indivior had a negative return on equity of 351.08% and a negative net margin of 0.17%. The company had revenue of $307.00 million during the quarter, compared to analysts' expectations of $302.25 million. On average, equities research analysts predict that Indivior PLC will post 1.62 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on INDV shares. Piper Sandler reiterated an "overweight" rating and set a $16.00 target price (up from $15.00) on shares of Indivior in a research report on Friday, October 25th. Craig Hallum reduced their price objective on shares of Indivior from $20.00 to $16.00 and set a "buy" rating on the stock in a research note on Friday, October 11th.

Indivior Profile

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.